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Background. Osteoporosis is the most common metabolic bone disease in the world. Since osteoporosis is clinically symptomless
until the ﬁrst fracture occurs, early diagnosis is critical. Calcium, along with calcium-binding and calcium-associated proteins,
plays an important role in homeostasis, maintaining healthy bone metabolism. This study is aimed at investigating the level of
calcium-binding/associated proteins, annexin A1, S100A4, and TMEM64, in peripheral blood mononuclear cells associated with
osteoporosis and its clinical signiﬁcance. Methods. The levels of mRNAs of annexin A1, S100A4, and TMEM64 in human
peripheral blood mononuclear cells were evaluated among 48 osteopenia and 23 osteoporosis patients compared to 17
nonosteoporotic controls. Total RNAs were isolated from clinical samples, and quantitation of mRNA levels was performed
using real-time quantitative PCR. Results. The levels of mRNAs for calcium-binding proteins, annexin A1 and S100A4, and
calcium-associated protein, TMEM64, in human peripheral blood mononuclear cells were signiﬁcantly reduced in osteopenia
and osteoporosis patients compared with nonosteoporotic controls (one-way ANOVA, P < 0:0001, P = 0:039, and P = 0:0195,
respectively). Annexin A1 and TMEM64 mRNAs were also signiﬁcantly reduced in female osteoporosis patients over the age of
50 years compared to nonosteoporotic controls (one-way ANOVA, P = 0:004 and P = 0:0037, respectively). ROC analysis
showed that the reduction in the level of mRNA for annexin A1, S100A4, or TMEM64 in the patients’ peripheral blood
mononuclear cells has a good diagnostic value for osteoporosis. Conclusions. The results show for the ﬁrst time that calcium-
binding/associated proteins, annexin A1 and TMEM64, could be future diagnostic biomarkers for osteoporosis.
1. Introduction
Osteoporosis is an age-related bone disease and has a severe
impact on public health and economy worldwide, due to
fragility fracture [1]. Since osteoporosis is clinically symp-
tomless until the ﬁrst fracture, there is a pressing need to
identify osteoporosis at an earlier stage. Osteoporosis arises
from an imbalance between bone-resorbing osteoclasts and
bone-producing osteoblasts [2]. Whilst osteoblasts are derived
from bone marrow cells [3], the bone-degrading osteoclasts
are derived by cell fusion and diﬀerentiation of precursor
monocyte blood cells [4], which can be found in the periph-
eral blood mononuclear cells (PBMCs) of a blood sample [5].
The PBMC fraction could be a source of markers which
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reﬂect changes in osteoclast activity in osteoporosis patients
and possibly in those with osteopenia, the milder, early form
of osteoporosis.
Calcium plays an important role in the development
of osteoclasts with the involvement of calcium-binding
proteins, such as annexins, S100 proteins, and proteins
involved with calcium signaling, such as TMEM64. Three
calcium-binding/associated proteins, annexin A1, S100A4,
and TMEM64, are expressed in monocyte cells (Gene
Expression Atlas: https://www.ebi.ac.uk/gxa/home). The cal-
cium-binding, EF-hand-containing S100 protein, S100A4,
has been identiﬁed in osteoclasts in developing mouse bone
[6]. In mice, knockdown of S100A4 with SiRNA led to a
higher bone mass and reduced numbers of osteoclasts [7],
suggesting its involvement in some way with bone degrada-
tion. Furthermore, it has been suggested that S100A4 pro-
tein not only prevents bone excess but also can prevent
cortical bone loss in estrogen-deprived mice [8]. Synchro-
nised fusion of mouse osteoclasts has been reported to
involve S100A4 and to depend upon a member of the cal-
cium-dependent, phospholipid-binding annexin protein
family, annexin A1 [9]. Annexin A1 is functional in the
human monocytic cell line, U937 [10], reducing its vascular
tethering and transmigration [11]. Furthermore, annexin A1
is an important mediator of the resolution of inﬂammation
[12], in part by enhancing leucocyte apoptosis [13]. Inﬂam-
matory diseases have been associated with osteoporotic bone
fragility [14].
The transmembrane protein, TMEM64, has been
reported to interact with and modulate the activity of the
protein, sarcoplasmic endoplasmic reticulum Ca2+ ATPase
2 (SERCA2), thereby enhancing RANKL-induced internal
calcium oscillations that are a part of the pathway of osteo-
clast generation [15].
Thus, the aim of this study was to ﬁnd out whether the
levels of mRNAs for annexin A1, S100A4, and TMEM64
were signiﬁcantly changed in the PBMCs of participants with
osteopenia or with osteoporosis compared to nonosteoporo-
tic controls.
2. Materials and Methods
2.1. Study Subjects. The participants in this study were men
and women volunteers living in Merseyside, England, in the
area covered by the Royal Liverpool and Broadgreen Univer-
sity Hospital NHS Trust. Participants were recruited from
referrals to the Nuclear Medicine Department at the Royal
Liverpool University Hospital. Diagnoses of osteopenia and
osteoporosis were made in accordance with the WHO guide-
lines. This study conformed to the principles of the 1964
Helsinki Declaration and its later amendments or compara-
ble ethical standards. The study was carried out under ethical
approval from the England Health Research Authority
National Research Ethics Service Committee, East of
England-Essex (REC reference 15/EE/0051) Ethics Commit-
tees. Informed consent was obtained from all participants
prior to sample collection. Details of the participants have
been described elsewhere [16] (Supplementary Table S1).
2.2. Isolation of Peripheral Blood Mononuclear Cells. Periph-
eral blood mononuclear cells (PBMCs) were isolated from
25mL blood samples and stored at -80°C, as described previ-
ously [16] including the ﬁnal 14,000 g centrifugation step to
yield a tight pellet of cellular material without maintaining
cell viability.
2.3. Isolation and Puriﬁcation of Total RNA. Total RNA from
human PBMCs was extracted using a combination of TRIzol
reagent and PureLink RNA mini kit (Thermo Fisher, UK),
according to themanufacturer’s recommendations as described
previously [16]. The resulting puriﬁed RNAs were eluted in
30 μL of RNase-free water and stored frozen at -80°C until
used. RNA concentrations and purity were measured using
a Thermo Scientiﬁc NanoDrop™ 2000 spectrophotometer.
2.4. Quantitation of mRNA Levels Using Real-Time
Quantitative PCR (RT-qPCR). Reverse transcription reac-
tions were carried out using the RT-First Strand kit, RT-
qPCR Primer Assays (Qiagen, UK), according to the manu-
facturer’s recommendations and as described previously
[16] on 500ng isolated RNA in a total volume of 20 μL with
a no reverse transcriptase, no DNA controls. Reverse
transcription reactions were diluted 1 : 20, and 10μL samples
were subjected to RT-qPCR for annexin A1, S100A4,
TMEM64, and glyceraldehyde-3-phosphate dehydrogenase
(GPDH) cDNAs, using the primers indicated in Table 1, with
a SYBR Green PCR kit (Qiagen, UK) in a Roche LightCycler
96 Real-Time PCR system (Roche, UK). Each set of reactions
was accompanied by the no-reverse-transcription, no-DNA
control sample. The relative levels of each RNA were
determined from the Ct value after normalization with
control mRNA, GPDH using the 2-ΔΔCT method [17]. Ct
values > 35 obtained from RT-qPCR were considered to
be below the level of detection of the methodology.
2.5. Statistical Analyses. Statistical analysis between two groups
used Student’s t-test and between multiple groups used
ANOVA with post hoc Bonferroni correction. Diagnostic
values were determined using receiver operator characteristic
curves. Statistical analyses were carried out using Stats Direct
3 (Altrincham, Cheshire). P values of <0.05 were considered
signiﬁcant as described previously [18].
3. Results
3.1. The Levels of mRNAs of Calcium-Binding/Associated
Proteins, Annexin A1, S100A4, and TMEM64, in the
Peripheral Blood Mononuclear Cells Are Reduced in
Osteoporosis Patients. The relative levels of mRNAs of cal-
cium-binding/associated proteins, annexin A1, S100A4, and
TMEM64, in isolated PBMC preparations were each signiﬁ-
cantly diﬀerent between nonosteoporosis control, osteope-
nia, or osteoporosis groups of participants (one-way
ANOVA, annexin A1 mRNA, Figure 1(a), Fð2 : 85Þ = 16:7,
P < 0:0001; TMEM64 mRNA, Figure 1(b), Fð2 : 84Þ = 4:13,
P = 0:0195; S100A4, Figure 1(c), Fð2 : 84Þ = 3:4, P = 0:039).
For annexin A1 mRNA, the strongly signiﬁcant decline was
evident between nonosteoporotic and osteopenia groups
(Figure 1(a) and Table 2; nonosteoporotic control group vs.
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osteopenia, 95%CI 0.208 to 0.476, P < 0:0001; nonosteoporotic
control group vs. osteoporosis, 95% CI 0.262 to 0.566,
P < 0:0001; osteoporosis vs. osteopenia, 95% CI -0.192
to 0.049, P = 0:242, post hoc Bonferroni correction).
For TMEM64, there was a gradual reduction in the order: non-
osteoporotic control, osteopenia, and osteoporosis groups
(Figure 1(b) and Table 2; nonosteoporotic control group
vs. osteopenia, 95% CI -0.004 to 0.0729, P = 0:0797; nonos-
teoporotic control group vs. osteoporosis, 95% CI 0.019 to
0.106, P = 0:0052; osteoporosis vs. osteopenia, 95% CI
-0.062 to 0.006, P = 0:1, post hoc Bonferroni correction). For
S100A4 mRNA, a signiﬁcant reduction was evident between
osteopenia and osteoporosis groups (Figure 1(c) and
Table 2; nonosteoporotic control group vs. osteopenia, 95%
CI -0.302 to 0.47, P = 0:666; nonosteoporotic control group
vs. osteoporosis, 95% CI 0.053 to 0.925, P = 0:0286; osteopo-
rosis vs. osteopenia, 95% CI -0.751 to -0.057, P =
0:0229, post hoc Bonferroni correction).
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Figure 1: Relative levels of mRNAs in peripheral blood mononuclear cells associated with osteoporosis. Levels of mRNAs encoding annexin
A1 (a, d, g), TMEM64 (b, e, h), and S100A4 (c, f, i) proteins were determined in the peripheral blood mononuclear cell preparations of
nonosteoporotic control subjects and patients suﬀering from osteopenia or osteoporosis shown as box and whisker plots. The levels are
shown for all participants (a, b, c), for participants who were not receiving treatment for osteoporosis (d, e, f), and for participants who
were not suﬀering from other disorders (g, h, i). On each box and whisker plot, the black diamond shows the median value, the cross
shows the mean value, and white and black circles denote outliers of 1.5 times and 3 times the interquartile range, respectively.
Table 1: Qiagen primers used to amplify speciﬁc mRNAs by RT-qPCR.
mRNA Gene symbol Accession number Primer sequence Qiagen catalogue
Annexin A1 ANXA1 NM_000700.2 5′TGTTTTAGCTCTGCTAAAAACTCCAG 3′ PPH02882E
S100 calcium-binding protein A4 S100A4 NM_002961 5′CAACTTGGACAGCAACAGGGAC 3′ PPH01313E
Transmembrane protein 64 TMEM64 NM_001008495.3 5′TTGGACTGCTTCCTACCCAGCTTC 3′ PPH10400A
Glyceraldehyde-3-phosphate
dehydrogenase
GAPDH NM_001256799 5′GGCGCTGCCAAGGCTGTGGGCA 3′ PPH00150F
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3.2. Analysis of Levels of mRNAs for Calcium-
Binding/Associated Proteins Associated with Treatment of
Osteoporosis and Other Disorders. For annexin A1 or
TMEM64, the signiﬁcant associations of reduced levels of
mRNA with osteopenia and osteoporosis were not aﬀected
when participants receiving treatment for osteoporosis were
excluded from the analysis (annexin A1 mRNA, one-way
ANOVA, Fð2, 68Þ = 12:7, P < 0:0001; Figure 1(d) and
Table 3; nonosteoporotic control group vs. osteopenia, 95%
CI 0.18 to 0.478, P < 0:0001; nonosteoporotic control group
vs. osteoporosis, 95%CI 0.232 to 0.603, P < 0:0001; osteoporo-
sis vs. osteopenia, 95%CI -0.248 to 0.071, P = 0:272; TMEM64
mRNA, one-way ANOVA, Fð2, 67Þ = 3:2, P = 0:046;
Figure 1(e) and Table 3; nonosteoporotic control group vs.
osteopenia, 95% CI -0.00096 to 0.0784, P = 0:056; nonosteo-
porotic control group vs. osteoporosis, 95% CI 0.011 to
0.109, P = 0:0168; osteoporosis vs. osteopenia, 95% CI
-0.063 to 0.02, P = 0:305; Bonferroni post hoc test). When
participants with nonosteoporotic medical disorders were
excluded, for annexin A1 or TMEM64, the signiﬁcant associ-
ations of reduced levels of mRNA with osteopenia and oste-
oporosis were not aﬀected (annexin A1 mRNA, one-way
ANOVA, Fð2, 66Þ = 11:8, P < 0:0001; Figure 1(g) and
Table 4; nonosteoporotic control group vs. osteopenia,
95% CI 0.176 to 0.477, P < 0:0001; nonosteoporotic control
group vs. osteoporosis, 95% CI 0.202 to 0.557, P < 0:0001;
osteoporosis vs. osteopenia, 95% CI -0.206 to 0.1, P = 0:491;
TMEM mRNA, one-way ANOVA, Fð2, 65Þ = 3:1, P = 0:05;
Figure 1(h) and Table 4; nonosteoporotic control group vs.
osteopenia, 95% CI -0.013 to 0.075, P = 0:166; nonosteoporo-
tic control group vs. osteoporosis, 95% CI 0.013 to 0.117,
P = 0:016; osteoporosis vs. osteopenia, 95% CI -0.078 to
0.01, P = 0:132, Bonferroni post hoc test).
However, for S100A4, the signiﬁcant association between
the reduction in S100A4 mRNA and osteoporosis was lost
when participants either receiving treatment for osteoporosis
or participants with nonosteoporotic medical disorders were
excluded from the analysis (osteoporosis treatment removed,
one-way ANOVA, Fð2, 67Þ = 1:17, P = 0:317; Figure 1(f) and
Table 3; other diseases removed one-way ANOVA, Fð2, 66Þ
= 1:39, P = 0:257; Figure 1(i) and Table 4), showing that
the relationship between S100A4 mRNA level and osteopo-
rosis was potentially aﬀected by treatment for osteoporosis
and by the presence of other disorders, whereas the relation-
ship between annexin A1 or TMEM64 mRNA and osteopo-
rosis was not.
3.3. The Levels of mRNAs of Calcium-Binding/Associated
Proteins Are Reduced in the Peripheral Blood Mononuclear
Cells of Female Osteoporosis Patients Aged over 50 Years.
To ﬁnd out whether the same results were obtained in
female osteoporosis patients aged over 50 years speciﬁcally,
the analyses were conﬁned to the 63 female subjects over
50 years of age. All three mRNAs showed the same trend
of a decrease in the mRNA level in the order: nonosteo-
porotic control, osteopenia, and osteoporosis observed when
all patients were included. Annexin A1 and TMEM64
mRNAs showed a signiﬁcant reduction between nonosteo-
porotic, osteopenia, and osteoporosis participants (annexin
A1 mRNA, one-way ANOVA, Fð2, 60Þ = 5:95, P = 0:004;
Figure 2(a) and Table 5; nonosteoporotic controls vs. osteo-
penia, 95% CI 0.114 to 0.493, P = 0:0021; nonosteoporotic
control group vs. osteoporosis, 95% CI 0.125 to 0.539,
P = 0:0022; osteoporosis vs. osteopenia, 95% CI -0.175 to
0.118, P = 0:699, Bonferroni post hoc test; TMEM64 mRNA,
one-way ANOVA, Fð2, 60Þ = 6:14, P = 0:0037; Figure 2(b)
and Table 5; nonosteoporotic control group vs. osteopenia,
95% CI 0.008 to 0.108, P = 0:0245; nonosteoporotic control
group vs. osteoporosis, 95% CI 0.041 to 0.15, P = 0:0009;
osteoporosis vs. osteopenia, 95% CI -0.077 to 0.0009,
P = 0:056, Bonferroni post hoc test). However, the changes
in S100A4 mRNA between the nonosteoporotic control
group, osteopenia, or osteoporosis patients were not signiﬁ-
cant in the female participants aged over 50 years (one-way
ANOVA, Fð2, 59Þ = 2:08, P = 0:134; Figure 2(c) and Table 5).
3.4.TheLevels ofmRNAs forAnnexinA1,TMEM64, or S100A4
in Peripheral Blood Mononuclear Cells from Participants with
or without Chronic Inﬂammatory Disorders. Osteoporosis
has been associated with chronic inﬂammatory disorders.
In order to ﬁnd out whether the reduction in the levels of
mRNAs for annexin A1, TMEM64, or S100A4 in peripheral
blood mononuclear cells was associated with the presence
of chronic diseases, the participants with osteopenia or oste-
oporosis were divided into those without and those with
reported chronic diseases or undergoing treatment with
steroids. The levels of annexin A1, TMEM64, or S100A4
mRNAs in PBMCs were not signiﬁcantly diﬀerent between
Table 2: Summary of statistical analysis on all participants.
mRNA Compared sample groups (n =number of participants) 95% conﬁdence interval P value (Bonferroni correction)
Annexin A1
Nonosteoporotic control (n = 17) vs. osteopenia (n = 48) 0.208 to 0.476 <0.0001
Nonosteoporotic control (n = 17) vs. osteoporosis (n = 23) 0.262 to 0.566 <0.0001
Osteoporosis (n = 23) vs. osteopenia (n = 48) -0.192 to 0.049 0.242
TMEM64
Nonosteoporotic control (n = 16) vs. osteopenia (n = 48) -0.004 to 0.0729 0.0797
Nonosteoporotic control (n = 16) vs. osteoporosis (n = 23) 0.019 to 0.106 0.0052
Osteoporosis (n = 23) vs. osteopenia (n = 48) -0.062 to 0.006 0.1
S100A4
Nonosteoporotic control (n = 17) vs. osteopenia (n = 47) -0.302 to 0.47 0.666
Nonosteoporotic control (n = 17) vs. osteoporosis (n = 23) 0.053 to 0.925 0.0286
Osteoporosis (n = 23) vs. osteopenia (n = 47) -0.751 to -0.057 0.0229
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Table 4: Summary of statistical analysis on participants without nonosteoporotic medical disorders.
mRNA Compared sample groups (n =number of participants) 95% conﬁdence interval P value (Bonferroni correction)
Annexin A1
Nonosteoporotic control (n = 17) vs. osteopenia (n = 36) 0.176 to 0.477 <0.0001
Nonosteoporotic control (n = 17) vs. osteoporosis (n = 16) 0.202 to 0.557 <0.0001
Osteoporosis (n = 16) vs osteopenia (n = 36) -0.206 to 0.1 0.491
TMEM64
Nonosteoporotic control (n = 16) vs. osteopenia (n = 36) -0.013 to 0.075 0.166
Nonosteoporotic control (n = 16) vs. osteoporosis (n = 16) 0.013 to 0.117 0.016
Osteoporosis (n = 16) vs osteopenia (n = 36) -0.078 to 0.01 0.132
S100A4
Nonosteoporotic control (n = 17) vs. osteopenia (n = 36) -0.224 to 0.54 0.413
Nonosteoporotic control (n = 17) vs. osteoporosis (n = 16) -0.077 to 0.828 0.102
Osteoporosis (n = 16) vs. osteopenia (n = 36) -0.608 to 0.172 0.269
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Figure 2: Relative levels of mRNAs in peripheral blood mononuclear cells associated with osteoporosis in females over the age of 50. Levels of
mRNAs encoding annexin A1 (a), TMEM64 (b), and S100A4 (c) proteins were determined in peripheral bloodmononuclear cell preparations
of nonosteoporotic control subjects and patients suﬀering from osteopenia or osteoporosis. On each box and whisker plot, the black diamond
shows the median value, the cross shows the mean value, and white and black circles denote outliers of 1.5 times and 3 times the interquartile
range, respectively.
Table 3: Summary of statistical analysis on participants with no osteoporosis treatment.
mRNA Compared sample groups (n =number of participants) 95% conﬁdence interval P value (Bonferroni correction)
Annexin A1
Nonosteoporotic control (n = 17) vs. osteopenia (n = 40) 0.18 to 0.478 <0.0001
Nonosteoporotic control (n = 17) vs. osteoporosis (n = 14) 0.232 to 0.603 <0.0001
Osteoporosis (n = 14) vs. osteopenia (n = 40) -0.248 to 0.071 0.272
TMEM64
Nonosteoporotic control (n = 16) vs. osteopenia (n = 40) -0.00096 to 0.0784 0.056
Nonosteoporotic control (n = 16) vs. osteoporosis (n = 14) 0.011 to 0.109 0.0168
Osteoporosis (n = 14) vs. osteopenia (n = 40) -0.063 to 0.02 0.305
S100A4
Nonosteoporotic control (n = 17) vs. osteopenia (n = 39) -0.273 to 0.556 0.498
Nonosteoporotic control (n = 17) vs. osteoporosis (n = 14) -0.124 to 0.906 0.134
Osteoporosis (n = 14) vs. osteopenia (n = 39) -0.694 to 0.195 0.267
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those with and those without known chronic inﬂammatory
disorders (Supplementary Figure S1).
3.5. Diagnostic Value of Calcium-Binding/Associated Protein
mRNAs for Osteoporosis. The levels of mRNAs for annexin
A1, S100A4, and TMEM64 were reduced in PBMCs from
osteoporosis patients compared to nonosteoporotic controls;
thus, the presence of these mRNAs marked the nonosteo-
porotic condition. ROC curve analysis for nonosteoporotic
controls and osteoporosis showed that, when all participants
were included, the areas under the ROC curves for annexin
A1, TMEM64, and S100A4 were 0.893, (Figure 3(a), 95%
CI 0.796 to 0.99; sensitivity 0.882, speciﬁcity 0.783), 0.742
(Figure 3(b), 95% CI 0.577 to 0.907; sensitivity 0.813, speci-
ﬁcity 0.696), and 0.783 (Figure 3(c), 95% CI 0.637 to 0.929;
sensitivity 0.882, speciﬁcity 0.652), respectively. The reduc-
tion of neither TMEM64 nor S100A4 discriminated well
nonosteoporotic controls from osteopenia (area under the
ROC curves, 0.6 and 0.55, respectively, not shown) or osteo-
penia and osteoporosis combined (area under the ROC
curves, 0.646 and 0.627, respectively, not shown). However,
for annexin A1, when nonosteoporotic controls were com-
pared with osteopenia, the area under the ROC curve was
0.805 (Figure 4(a), 95% CI 0.682 to 0.928; sensitivity 0.588,
speciﬁcity 0.917) and when compared with osteopenia and
osteoporosis combined, the area under the ROC curve was
0.833 (Figure 4(b), 95% CI 0.729 to 0.938; sensitivity 0.588,
speciﬁcity 0.93).
When the analysis was conﬁned to females over the age of
50 years, similar results were obtained, with areas under the
ROC curves for annexin A1, TMEM64, and S100A4 mRNAs
being 0.809 (Figure 3(d), 95% CI 0.635 to 0.983; sensitivity
0.778, speciﬁcity 0.722), 0.765 (Figure 3(e), 95% CI 0.541
to 0.99; sensitivity 0.778, speciﬁcity 0.722), and 0.765
(Figure 3(f), 95% CI 0.583 to 0.948; sensitivity 1.0, speciﬁcity
0.444), respectively. Neither TMEM64 nor S100A4 mRNAs
discriminated well nonosteoporotic controls from osteopenia
(area under the ROC curves, 0.614 and 0.543, respectively,
not shown) or osteopenia and osteoporosis combined (area
under the ROC curves, 0.667 and 0.618, respectively, not
shown). However, for annexin A1 mRNA, when nonosteo-
porotic controls were compared with osteopenia, the area
under the curve was 0.747 (Figure 4(c), 95% CI 0.563 to
0.931; sensitivity 0.556, speciﬁcity 0.861) and when com-
pared with osteopenia and osteoporosis combined, the area
under the curve was 0.767 (Figure 4(d), 95% CI 0.598 to
0.937; sensitivity 0.556, speciﬁcity 0.87).
4. Discussion
Three mRNAs, encoding calcium-binding/associated pro-
teins, ANXA1, S100A4, and TMEM64, were found to be at
a lower level in the PBMC preparations from osteoporosis
patients than nonosteoporotic controls. The reductions of
S100A4 mRNA levels were found to be due to participants
with other disorders, those receiving existing treatments for
osteoporosis, males, and under 50-year olds. In contrast,
the observed reductions in annexin A1 or TMEM64 mRNAs
were not aﬀected by any of these factors.
Annexin A1 protein and, to a lesser extent, TMEM64
protein are found in the CD14+/CD16-negative monocytes
[19] (Gene Expression Atlas: https://www.ebi.ac.uk/gxa/
home). These cells have been shown to be the likely source
of osteoclasts by diﬀerentiation in vitro of cells from normal
human subjects [20]. For TMEM64 mRNA in PBMCs, the
observed reduction in the level with osteoporosis in the pres-
ent experiments seems unexpected in view of previous results
with TMEM64 knockout mice, in which reduced levels of
TMEM64 mRNA resulted in a phenotype of increased bone
mass [21]. Apart from possible species diﬀerences between
mouse and human, such as observed for annexin A1 [9],
the diﬀerence between the present results and the TMEM64
mouse knockout results could arise from the cell prepara-
tions being examined in the two studies. In the knockout
mice, there was a reduction in bone-associated, fully diﬀer-
entiated osteoclasts [21], whereas in the present study, the
TMEM64 mRNA levels were examined in the blood PBMC
fraction, which contains monocytes as yet undiﬀerentiated
into osteoclasts [4].
Annexin A1 has been reported to be present in the
human U937 cultured monocyte cell line, where it has been
reported to reduce adhesion of U937 cells to bone marrow
endothelial cells by directly interacting with α4 integrin
and competing with binding of the endothelial α4 integrin
receptor, VCAM-1 [11]. A reduction in annexin A1 mRNA,
and thus possibly a reduction in annexin A1 protein, in
monocytes could therefore result in increased retention of
Table 5: Summary of statistical analysis on female participants over the age of 50.
mRNA Compared sample groups (n =number of participants) 95% conﬁdence interval P value (Bonferroni correction)
Annexin A1
Nonosteoporotic control (n = 9) vs. osteopenia (n = 36) 0.114 to 0.493 0.0021
Nonosteoporotic control (n = 9) vs. osteoporosis (n = 18) 0.125 to 0.539 0.0022
Osteoporosis (n = 18) vs. osteopenia (n = 36) -0.175 to 0.118 0.699
TMEM64
Nonosteoporotic control (n = 9) vs. osteopenia (n = 36) 0.008 to 0.108 0.0245
Nonosteoporotic control (n = 9) vs. osteoporosis (n = 18) 0.041 to 0.15 0.0009
Osteoporosis (n = 18) vs. osteopenia (n = 36) -0.077 to 0.0009 0.056
S100A4
Nonosteoporotic control (n = 9) vs. osteopenia (n = 35) -0.406 to 0.601 0.7
Nonosteoporotic control (n = 9) vs. osteoporosis (n = 18) -0.095 to 1.01 0.103
Osteoporosis (n = 18) vs. osteopenia (n = 35) -0.7486 to 0.033 0.072
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monocytes by endothelial cells in the bone marrow and
reduced numbers in peripheral blood mononuclear cells.
However, the PBMC fractions consist of only 20-40%
monocytes and a low percentage of polymorphonuclear cells
(1-4%), but amajority (60-80%)of cells inPBMCpreparations
are lymphocytes [22].TMEM64mRNAispresent at a low level
in both T and B lymphocytes and is more abundant in natural
killer cells (GeneExpressionAtlas: https://www.ebi.ac.uk/gxa/
home). Annexin A1 (lipocortin 1) has been reported to be
present at a consistent level in many T lymphocyte subtypes
and at a higher level in natural killer cells [19], but not
present in B lymphocytes (Gene Expression Atlas:
https://www.ebi.ac.uk/gxa/home). Thus, it is possible that
the observed reductions in annexin A1 and TMEM64
mRNAs arise in the lymphocyte populations in the PBMC
preparations. It is not known whether there are speciﬁc dif-
ferences in the cell types populating PBMCs of nonosteo-
porotic individuals and osteopenia and osteoporosis
patients. However, T lymphocytes [23, 24] and natural killer
cells [25] have been reported to contribute to osteoporosis
by their activation and production of osteoclastogenic cyto-
kines, but the observation that various T cell subtypes can
exhibit either osteoclastogenic, e.g., Thy 17, or antiosteoclas-
togenic activity, e.g., Thy1 [26], suggests that there is a bal-
ance between pro- and antiosteoclastic activity in T cell
subtypes. Whilst, little, if anything, is known about any pos-
sible role of TMEM64 in these processes in T lymphocytes,
the presence of annexin A1, on the other hand, has been
widely associated with the resolution of inﬂammatory disor-
ders [12, 13, 27]. Thus, a change in the balance of T cell
osteoclastogenic activity, arising from the reduced annexin
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Figure 4: Diagnostic values of annexin A1 for nonosteoporotic
controls vs osteopenia and osteoporosis. ROC curves are shown
for the mRNA for annexin A1 for all participants (a, b) and
female participants over the age of 50 (c, d), comparing
nonosteoporotic controls with osteopenia (a, c) and
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The circled point indicates the optimum cut-oﬀ.
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A1 mRNA levels in PBMCs from osteopenia/osteoporosis
patients, could contribute to their osteopenia/osteoporosis.
However, this might not be consistent with the observation
on the present group of participants that the levels of
annexin mRNA in the PBMCs of participants with chronic
inﬂammatory disorders were not signiﬁcantly diﬀerent
from those without chronic inﬂammatory disorders, either
when all participants or when only the female-over-50
group were considered.
ROC curve analysis for the changes in these mRNAs
showed moderate accuracy for the areas under the curves
[28]. Annexin A1 exhibited the best trade-oﬀ of sensitivity
against speciﬁcity of the three possible markers for all partic-
ipants when nonosteoporotic controls were compared with
osteoporosis (area under the curve, 0.893), with osteopenia
(area under the curve, 0.805), or with osteopenia and osteo-
porosis combined (area under the curve, 0.833) or when only
females over the age of 50 were included (areas under the
curves, 0.809, 0.747, and 0.767, respectively).
In conclusion, this study demonstrates for the ﬁrst time
that the levels of mRNAs of annexin A1 and TMEM64 in
peripheral blood mononuclear cells are reduced in associa-
tion with osteoporosis, at least in this group of patients with
loss of annexin A1 mRNA in peripheral blood mononuclear
cells being a good marker for osteopenia/osteoporosis.
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